首页> 外文期刊>Nature clinical practice. Rheumatology >Primer: establishing a clinical trial unit - regulations and infrastructure.
【24h】

Primer: establishing a clinical trial unit - regulations and infrastructure.

机译:底漆:建立临床试验部门-法规和基础设施。

获取原文
获取原文并翻译 | 示例
           

摘要

The performance of clinical trials can be very rewarding for the practicing or academic clinical rheumatologist. There are at least 50 new compounds - small molecules and biologics - in development for rheumatic diseases such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, scleroderma, gout and fibromyalgia. Clinical trials are important to try to determine the appropriate use of these compounds, as well as to answer questions about their safety. To carry out clinical trials effectively, the physician-investigator must be aware of, and adhere to, the regulatory requirements. The purpose of this article is to review these requirements in depth, as well as to discuss the infrastructure required to establish a successful clinical trial unit.
机译:对于临床或风湿病临床医师来说,临床试验的执行可能会非常有益。针对风湿性疾病,例如类风湿性关节炎,骨关节炎,系统性红斑狼疮,强直性脊柱炎,银屑病关节炎,硬皮病,痛风和纤维肌痛,至少有50种新化合物(小分子和生物制剂)正在开发中。临床试验对于尝试确定这些化合物的适当用途以及回答有关其安全性的问题非常重要。为了有效地进行临床试验,医师研究人员必须了解并遵守法规要求。本文的目的是深入研究这些要求,并讨论建立成功的临床试验单位所需的基础结构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号